Metformin Cuts Cardiac Dysfunction Risk 31% With VEGF Inhibitors, AHA Study Finds

Metformin cut the risk of cardiac dysfunction by 31 percent in patients receiving vascular endothelial growth factor inhibitors, according to a retrospective cohort study presented Saturday at the American Heart Association Scientific Sessions in Chicago.

The finding arrives as cardio-oncology teams search for affordable, well-tolerated tools to protect the heart during cancer therapy. VEGF inhibitors — a backbone of treatment for renal-cell carcinoma and other malignancies — are known to strip nitric oxide from the endothelium and to inhibit AMP-activated protein kinase, or AMPK, disrupting cellular energy balance.

Metformin, a diabetes staple for decades, does the opposite: it activates endothelial nitric oxide synthase and AMPK, offering a mechanistic counterweight.

"It's a low-cost medication. It's not associated with many side effects. He acknowledged the limits of the composite endpoint, noting that standardized echocardiographic surveillance would be more reliable but the database lacked the granularity to support it.”

“I’m a little cautious about using metformin in patients who do not have diabetes or do not have an indication for metformin,” Haroun said.

The analysis drew on a matched cohort of patients treated with VEGF inhibitors. In the overall population, metformin use was associated with lower all-cause mortality — 19.8 percent versus 23.0 percent, a hazard ratio of 0.83 — and less new-onset metastatic cancer, 10.6 percent versus 12.8 percent, hazard ratio 0.81.

Both differences reached statistical significance. When the researchers restricted the analysis to patients with type 2 diabetes, however, the mortality and metastatic-disease signals disappeared. The association between metformin and the heart-failure composite persisted.

Haroun pointed to the Diabetes Prevention Program, published in the New England Journal of Medicine in 2002, which showed metformin prevented type 2 diabetes most effectively in younger patients, those with a body-mass index above 35, and those with elevated hemoglobin A1c. The goal now, he said, is to identify the patients most likely to benefit from cardioprotection during VEGF-inhibitor therapy.

Founded in Chicago in 1924 by six cardiologists as a professional society, the American Heart Association now operates from Dallas and coordinates more than 33 million volunteers. A 1949 radio fundraiser called The Walking Man brought in $1.5 million — equivalent to $17–20 million today — marking the turning point that enabled the organization to begin funding research; since then it has invested over $6.1 billion in cardiovascular, cerebrovascular and brain health studies.

No randomized trial has yet tested metformin for cardioprotection in cardio-oncology. Haroun favors a randomized trial comparing metformin with other diabetes therapies in patients with type 2 diabetes. His team has not studied hypertension or other VEGF-inhibitor toxicities, which he identified as targets for future research.